Renovaro (RENB) Competitors $0.23 -0.01 (-2.55%) As of 03:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RENB vs. CCCC, CRBU, BTMD, ELDN, LYEL, CRDF, BIOA, CTMX, ACOG, and SLSShould you be buying Renovaro stock or one of its competitors? The main competitors of Renovaro include C4 Therapeutics (CCCC), Caribou Biosciences (CRBU), biote (BTMD), Eledon Pharmaceuticals (ELDN), Lyell Immunopharma (LYEL), Cardiff Oncology (CRDF), BioAge Labs (BIOA), CytomX Therapeutics (CTMX), Alpha Cognition (ACOG), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical products" industry. Renovaro vs. Its Competitors C4 Therapeutics Caribou Biosciences biote Eledon Pharmaceuticals Lyell Immunopharma Cardiff Oncology BioAge Labs CytomX Therapeutics Alpha Cognition SELLAS Life Sciences Group C4 Therapeutics (NASDAQ:CCCC) and Renovaro (NASDAQ:RENB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings. Which has more volatility and risk, CCCC or RENB? C4 Therapeutics has a beta of 2.97, meaning that its stock price is 197% more volatile than the S&P 500. Comparatively, Renovaro has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Do analysts rate CCCC or RENB? C4 Therapeutics currently has a consensus price target of $8.00, suggesting a potential upside of 173.50%. Given C4 Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe C4 Therapeutics is more favorable than Renovaro.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score C4 Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Renovaro 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is CCCC or RENB more profitable? Renovaro has a net margin of 0.00% compared to C4 Therapeutics' net margin of -325.88%. C4 Therapeutics' return on equity of -53.91% beat Renovaro's return on equity.Company Net Margins Return on Equity Return on Assets C4 Therapeutics-325.88% -53.91% -33.26% Renovaro N/A -60.38%-47.04% Do institutionals and insiders have more ownership in CCCC or RENB? 78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 71.4% of Renovaro shares are held by institutional investors. 8.7% of C4 Therapeutics shares are held by company insiders. Comparatively, 0.5% of Renovaro shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, CCCC or RENB? Renovaro has lower revenue, but higher earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Renovaro, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioC4 Therapeutics$35.58M5.85-$105.32M-$1.58-1.85RenovaroN/AN/A-$88.43M-$0.77-0.30 Does the media prefer CCCC or RENB? In the previous week, C4 Therapeutics had 2 more articles in the media than Renovaro. MarketBeat recorded 5 mentions for C4 Therapeutics and 3 mentions for Renovaro. Renovaro's average media sentiment score of 0.96 beat C4 Therapeutics' score of -0.03 indicating that Renovaro is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment C4 Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Renovaro 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryC4 Therapeutics beats Renovaro on 10 of the 15 factors compared between the two stocks. Get Renovaro News Delivered to You Automatically Sign up to receive the latest news and ratings for RENB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RENB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RENB vs. The Competition Export to ExcelMetricRenovaroMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$40.10M$3.13B$5.71B$9.79BDividend YieldN/A2.21%3.77%4.10%P/E Ratio-0.3020.9230.9125.28Price / SalesN/A232.70404.2188.50Price / CashN/A41.5625.2228.45Price / Book0.269.779.536.01Net Income-$88.43M-$54.74M$3.26B$265.34M7 Day Performance-2.14%8.37%4.66%2.89%1 Month Performance-26.48%7.94%5.35%1.61%1 Year Performance-65.65%18.27%32.14%25.61% Renovaro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RENBRenovaro1.7123 of 5 stars$0.23-2.6%N/A-64.8%$40.10MN/A-0.3020Short Interest ↓CCCCC4 Therapeutics1.7953 of 5 stars$2.29-5.6%$8.00+250.1%-57.9%$162.62M$35.58M-1.45150CRBUCaribou Biosciences3.3002 of 5 stars$1.75+2.0%$6.67+282.0%-5.3%$162.29M$9.99M-1.08100News CoverageEarnings ReportAnalyst DowngradeAnalyst RevisionBTMDbiote2.5043 of 5 stars$2.97+5.1%$6.00+102.4%-49.6%$162.22M$197.19M3.29194ELDNEledon Pharmaceuticals1.8719 of 5 stars$2.69-0.7%$10.00+271.7%-3.7%$161.08MN/A-1.2810Earnings ReportShort Interest ↑LYELLyell Immunopharma3.2969 of 5 stars$10.27-2.9%$15.00+46.1%-56.6%$160.17M$60K-0.41270Earnings ReportAnalyst DowngradeCRDFCardiff Oncology1.9535 of 5 stars$2.40+2.8%$10.10+321.7%+2.1%$159.34M$680K-2.7520BIOABioAge LabsN/A$4.40+1.4%N/AN/A$157.74MN/A0.00N/ACTMXCytomX Therapeutics3.9442 of 5 stars$1.95-15.8%$5.75+195.6%+59.2%$156.81M$138.10M3.47170Gap UpACOGAlpha Cognition1.6986 of 5 stars$9.77-2.2%$20.00+104.7%N/A$156.52MN/A-8.14N/AEarnings ReportAnalyst DowngradeSLSSELLAS Life Sciences Group2.7079 of 5 stars$1.54-0.3%$7.00+356.0%+23.5%$153.16M$1M-4.0410Earnings ReportOptions Volume Related Companies and Tools Related Companies C4 Therapeutics Alternatives Caribou Biosciences Alternatives biote Alternatives Eledon Pharmaceuticals Alternatives Lyell Immunopharma Alternatives Cardiff Oncology Alternatives BioAge Labs Alternatives CytomX Therapeutics Alternatives Alpha Cognition Alternatives SELLAS Life Sciences Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RENB) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renovaro Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Renovaro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.